Loading
Latest filing published 22 Aug 2023 for HOOKIPA Pharma Inc., €4,657.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Reinhard Kandera (finance chief) discloses dealings in HOOKIPA Pharma Inc. to SEC (Form 4). In total, 5 filings cover trades dated from 20 July 2020 to 21 August 2023.
On the market, this insider has only ever bought: 3 purchases, €20k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 2 share grants. 2023 to date brings 3 purchases and no sales.
Half of the purchases are above €5,252 and half below. The 3 purchases reviewed show no overlap with other insiders buying the same stock within a month.
The latest filing, published on 22 August 2023, reports an open-market purchase of €4,657 in HOOKIPA Pharma Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations